Fresenius stock holds its ground despite one-year loss

Fresenius stock (ISIN DE0005785604) has lagged over a twelve-month horizon, with a one-year investment resulting in a negative performance despite a closing price of 44.79 EUR on Xetra on September 1, 2026, according to a performance analysis by finanzen.ch.

One-year performance under pressure

Data compiled by finanzen.ch on September 2, 2026 shows that Fresenius shares would have been worth 963.12 EUR at the Xetra closing price of 44.79 EUR on September 1, 2026 for an investor who put 1,000 EUR into the stock one year earlier.

The same analysis points out that this development corresponds to a clear loss over twelve months, underperforming the broader DAX 40, in which Fresenius SE is included as a healthcare stock.

DAX listing anchors the stock in the region

As a member of the DAX 40 and with its primary listing in Frankfurt, Fresenius remains a core healthcare exposure for many German and Swiss investors who follow Xetra prices closely.

The finanzen.ch review also indicates that Fresenius stock was quoted at 41.61 Swiss francs on September 2, 2026 in Swiss trading, a decline of 1.69% on that day, underscoring that the weakness is visible across European trading venues, not just on Xetra.

Healthcare portfolio as long-term driver

Fresenius generates its revenue in areas such as hospital operations, medical services and infusion and nutrition therapies, which are typically less cyclical than many industrial sectors.

For investors, the key question is whether the defensive business profile and exposure to demographics and healthcare spending can, over time, compensate for the recent share price weakness seen in the one-year performance numbers.

Fresenius stock on Xetra

Based on the Xetra closing price of 44.79 EUR as of September 1, 2026 reported by finanzen.ch, Fresenius stock is trading clearly below the level implied by a break-even one-year investment, highlighting the gap that would need to be closed for a full recovery.